Mucopolysaccharidosis type ii (mps ii)
Drug research and approvals for mucopolysaccharidosis type ii (mps ii): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 8 studies of mucopolysaccharidosis type ii (mps ii) are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 2 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 8
- Trials authorized in Canada: 5
- FDA orphan approvals: 2
- EU medicines: 1
Recruiting Now
Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗- A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)NCT07640984 · Phase 1 / Phase 2 · JCR Pharmaceuticals Co., Ltd. · starts Sep 9, 2026
- Registry of Patients Diagnosed With Lysosomal Storage DiseasesNCT05619900 · Not reported · University of California, San Francisco · starts May 31, 2022
- PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)NCT04532047 · Phase 1 · University of California, San Francisco · starts Jul 1, 2021
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICNCT04528355 · Not reported · Paul Szabolcs · starts Aug 20, 2020
- MPS (RaDiCo Cohort) (RaDiCo-MPS)NCT06036693 · Not reported · Institut National de la Santé Et de la Recherche Médicale, France · starts Dec 20, 2017
- UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsNCT02254863 · Phase 1 · Joanne Kurtzberg, MD · starts Sep 1, 2014
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · Phase 2 · Paul Szabolcs · starts Feb 4, 2014
- Longitudinal Study of Neurodegenerative DisordersNCT03333200 · Not reported · University of Pittsburgh · starts Jan 11, 2012
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 31, 2024 | Effect of adalimumab on musculoskeletal disease in mucopolysaccharidosis types i, ii, iva and viHUMIRA | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | Ongoing |
| Oct 30, 2023 | An open-label extension to investigate the long-term safety, tolerability, and efficacy of dnl310 in patients with mucopolysaccharidosis type ii (mps ii) from…DNL310 | Denali Therapeutics Inc. | Ongoing |
| Oct 26, 2022 | A phase 1/2/3 multicenter, open label study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of rgx-121 in pediatric subjects with mps ii…RGX-121 / RAPAMUNE / PROGRAF / PREDNISOLONE / MEDROL | REGENXBIO | Closed |
| Jul 13, 2022 | A phase 1 open-label dose escalation study to evaluate the safety and efficacy of hmi-203 in enzyme replacement therapy (ert)-treated adults with…HMI-203 / DEXAMETHASONE / TACROLIMUS ER (ADVAGRAF) | HOMOLOGY MEDICINES, INC. | Closed |
| Jun 7, 2022 | A phase 2/3, multicenter, double-blind, randomized study to determine the efficacy and safety of dnl310 vs idursulfase in pediatric participants with…DNL310 | Denali Therapeutics Inc. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 24, 2026 | Avlayahtreatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or… | Denali Therapeutics Inc. | Approved |
| Jul 24, 2006 | ElapraseIndicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Oct 16, 2025 | sleeping beauty transposon-engineered autologous…treatment of mucopolysaccharidosis type II | Immusoft CA, Inc. | Designated |
| Oct 15, 2018 | Humanized IgG-1 antibody targeting human transferrin…Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome | JCR Pharmaceuticals Co., Ltd. | Designated |
| Dec 8, 2015 | non-replicating recombinant adeno-associated virus (AAV)…Treatment of Mucopolysaccharidosis Type II | REGENXBIO, Inc. | Designated |
| May 15, 2013 | HIRMAb-IDSTreatment of mucopolysaccharidosis Type II (Hunter Syndrome) | ArmaGen Technologies, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jan 8, 2007 | Elapraseidursulfase | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA